Form 4: Rocket Pharma CMO Expands Equity Holdings

Rocket Pharmaceuticals' Chief Medical Officer, Syed Ali-aamir Rizvi, significantly increased his beneficial ownership through new restricted stock unit and stock option grants.

Summary

• Syed Ali-aamir Rizvi, Chief Medical Officer of Rocket Pharmaceuticals, Inc. (RCKT), acquired additional equity securities.
• On October 6, 2025, Rizvi was granted 283,018 restricted stock units (RSUs) which convert to common stock on a one-for-one basis.
• These RSUs will vest one-third on October 6, 2026, with the remainder vesting in equal quarterly installments over the subsequent two years, contingent on continued employment.
• An additional 62,893 RSUs were granted on October 6, 2025, vesting one-half on October 6, 2026, and the remaining half on the second anniversary of the grant date (October 6, 2027), also subject to continued employment.
• Rizvi also received 383,854 non-qualified stock options (NQSOs) with an exercise price of $3.18 per share on October 6, 2025.
• These NQSOs will vest one-third on October 6, 2026, with the remaining options vesting in equal quarterly installments over the following two years, subject to continued employment.
• The stock options have an expiration date of October 6, 2035.
• Following these transactions, Rizvi beneficially owns 345,911 shares of common stock (non-derivative) and 383,854 stock options (derivative).

Sentiment

Score: 6

Explanation: The filing reports routine executive compensation in the form of equity grants. While not directly impacting financial results, it indicates continued executive alignment with shareholder interests, which is generally a positive signal for corporate governance and long-term strategy.

Positives

• Increased equity ownership by a key executive, the Chief Medical Officer, aligns management's interests with those of shareholders.
• The grants are performance-incentivizing, tied to continued employment and future value creation.

Future Outlook

This Form 4 filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the vesting schedules of the equity awards which are contingent on continued employment.

Industry Context

Executive equity grants, such as restricted stock units and stock options, are a standard component of compensation packages in the biotechnology and pharmaceutical industries. They are designed to attract, retain, and incentivize key talent by aligning their financial interests with the long-term performance of the company and its shareholders. The vesting schedules typically encourage long-term commitment.

Comparison to Industry Standards

• This Form 4 filing does not provide sufficient detail to compare the specific equity grants to industry benchmarks or comparable companies.
• However, the structure of the grants, involving RSUs and NQSOs with multi-year vesting schedules, is a common practice for executive compensation in the biotech sector, similar to practices observed at companies like Sarepta Therapeutics or BioMarin Pharmaceutical, which also utilize long-term equity incentives for their leadership.

Stakeholder Impact

• Shareholders: Increased alignment of the Chief Medical Officer's financial interests with long-term shareholder value.
• Employees: May signal stability in executive leadership and a commitment to retaining key personnel.

Next Steps

• Vesting of 283,018 RSUs: One-third on October 6, 2026, with remaining shares vesting quarterly over the subsequent two years.
• Vesting of 62,893 RSUs: One-half on October 6, 2026, and the remaining half on October 6, 2027.
• Vesting of 383,854 NQSOs: One-third on October 6, 2026, with remaining options vesting quarterly over the subsequent two years.

Key Dates

Keywords

Rocket Pharmaceuticals, RCKT, Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, Equity Grant, Syed Ali-aamir Rizvi, Chief Medical Officer